AC-430(AC-430) - 药物靶点：JAK2_专利_临床

概要

基本信息

药物类型

小分子化药

别名

AC 430、AC-410/AC-409、AC410/AC409

+ [1]

靶点

JAK2

作用机制

JAK2抑制剂(酪氨酸蛋白激酶JAK2抑制剂)

治疗领域

肿瘤免疫系统疾病血液及淋巴系统疾病+ [2]

在研适应症-

非在研适应症

炎症白血病类风湿关节炎

原研机构

Daiichi Sankyo Co., Ltd.

在研机构-

非在研机构

Daiichi Sankyo, Inc.

Daiichi Sankyo Co., Ltd.Ambit Biosciences (Canada) Corp.

最高研发阶段终止临床1期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构

分子式C19H17BrFN5O

InChIKeyOXLABSVIPVOENF-UHFFFAOYSA-N

CAS号1359828-49-1

关联

1

项与 AC-430 相关的临床试验

NCT01287858 / Completed临床1期

A Phase 1, Randomized, Double Blind, Placebo Controlled, Sequential, Ascending Single-Dose and Multiple-Dose First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AC430 in Healthy Subjects

AC430 will be administered, orally under fasting conditions (fasting 4 hours before and 2 hours after dosing) with approximately 240 mL of water either once daily or twice daily. It is designed to assess the safety, tolerability, and pharmacokinetics of single and multiple oral doses of AC430.

开始日期2010-11-01

申办/合作机构

Daiichi Sankyo, Inc.

100 项与 AC-430 相关的临床结果

登录后查看更多信息

100 项与 AC-430 相关的转化医学

登录后查看更多信息

100 项与 AC-430 相关的专利（医药）

登录后查看更多信息

21

项与 AC-430 相关的文献（医药）

2024-12-10·Lakartidningen

[Structured switching from warfarin to DOAC in patients with atrial fibrillation].

Article

作者: Björkenheim, Anna ; Nylund, Konrad ; Al-Hadrawi, Zainab

In patients with atrial fibrillation (AF) at risk of stroke, direct oral anticoagulants (DOAC) have been shown to be at least as effective as warfarin, offering advantages like reduced monitoring requirements and lower bleeding risks. Disadvantages include limited data in patients with severe chronic kidney disease and higher patient costs. In mid-2021, Region Örebro County, Sweden, decided to switch suitable patients with AF from warfarin to DOAC. Out of the 823 patients receiving warfarin therapy, 732 were identified as suitable candidates for DOAC, and 89 percent of these patients were successfully switched. Switching from warfarin to DOAC offers superiority and simplifies treatment and monitoring. However, individual needs and risk factors must be carefully considered before switching. As many patients in Sweden continue to be prescribed warfarin, this initiative could potentially model for other regions.

2024-09-01·JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION

Impact of shared decision-making in Taiwanese patients with atrial fibrillation eligible for novel oral anticoagulant therapy

Article

作者: Lin, Tsung-Hsien ; Wu, Wei-Tsung ; Chien, Szu-Chi ; Huang, Hung-Kain ; Wu, Yen-Wen ; Chen, Ching-Pei ; Yang, Yuan-Po ; Huang, Chi-Cheng ; Chu, Chun-Yuan ; Tu, Chung-Ming ; Jhuo, Shih-Jie

BACKGROUND/PURPOSE:

Shared decision-making (SDM) promotes patient awareness about medical conditions and treatments, facilitating patient involvement in care decisions. This two-stage multicenter study evaluated impacts of SDM in Taiwanese adults with atrial fibrillation (AF) eligible for novel oral anticoagulant (NOAC) therapy.

METHODS:

Participants were NOAC-naïve (part I) or dabigatran-experienced (part II). During Stage I, part I participants (n = 124) completed a semi-structured survey (understanding evaluation sections only) before and after viewing SDM materials on stroke prevention for AF. Surveys collected data on anxiety about AF, confidence in healthcare professionals, usefulness of the SDM materials, and perception of different NOACs. During Stage II, part I participants after being prescribed NOACs, and part II participants completed another survey to compare impacts of SDM.

RESULTS:

During Stage I, dabigatran was the preferred NOAC after viewing the SDM materials among 90% of part I participants. During Stage II, both part I (n = 87) and part II participants (n = 104) completed another survey. Fewer part I participants were anxious about AF (p < 0.01), and more had confidence in healthcare professionals (p < 0.01) after viewing SDM materials than before. Most part I participants (≥90%) rated the SDM materials as "very helpful". In Stage II, participants viewing SDM before initiating dabigatran had lower anxiety (part I, 43%; part II, 53%; p < 0.01) and a higher trust (part I, 92%; part II, 84%; p < 0.01).

CONCLUSION:

In conclusion, SDM reduced anxiety and improved trust in healthcare professionals among NOAC-naïve participants with AF.

2024-06-01·Journal of Arrhythmia

Impact of left ventricular diastolic function and direct oral anticoagulant use for predicting embolic events in patients with heart failure and atrial fibrillation

Article

作者: Hayama, Hiromasa ; Yamamoto, Jumpei ; Hiroi, Yukio ; Hara, Hisao ; Enomoto, Yoshinari ; Yamamoto, Masaya

Abstract:

Background:

Patients with atrial fibrillation (AF) and heart failure (HF) have high stroke risk owing to left atrial dysfunction. However, anticoagulation is a concern in patients with high bleeding risk. We aimed to identify independent predictors of stroke in HF patients with AF.

Methods:

We retrospectively examined 320 patients (mean age 79 ± 12 years, 163 women) hospitalized with acute HF complicated by AF between January 2014 and December 2018. Patients were followed from admission until ischemic stroke or systemic embolism (SSE) onset or death or were censored at the last contact date or September 2023.

Results:

SSE occurred in 40 patients (median follow‐up of 528 days). Multivariate Cox regression analysis identified age (hazard ratio [HR] 1.04, 95% confidence interval [CI] 1.00–1.07, p = .034), direct oral anticoagulant (DOAC) use (HR 0.26, 95% CI 0.11–0.60, p = .002), and early diastolic peak flow velocity to early diastolic peak annular velocity (E/e'; HR 1.05, 95% CI 1.02–1.08, p < .001) to be independent predictors of SSE, whereas left atrial reservoir strain was not. After determining an appropriate E/e' cutoff by receiver‐operating characteristic curve analysis and adjusting the multivariate Cox model, E/e' ≥17.5 (HR 3.30, 95% CI 1.56–6.83, p = .001) independently predicted SSE. The results were consistent with no interaction in the subanalysis except for gender.

Conclusion:

Elderly patients not on DOACs with elevated E/e' may be at higher risk of stroke, suggesting that DOACs should be the first choice for patients with elevated E/e' and aggressive additional prophylaxis and careful follow‐up are needed.

100 项与 AC-430 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB12535

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
类风湿关节炎	临床1期	美国	Daiichi Sankyo, Inc.	2010-11-01
白血病	临床1期	美国	Ambit Biosciences (Canada) Corp.	-
白血病	临床1期	-	Daiichi Sankyo Co., Ltd.	-
炎症	临床前	美国	Ambit Biosciences (Canada) Corp.	-